-

06:06:57 PM

EFTR Stock News

EFTR - eFFECTOR Therapeutics Inc

03/08/23 4:01 PM

Nasdaq : EFTR

earningslow float

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Zotatifin continued to demonstrate favorable activity and tolerability, including two previously reported confirmed partial responses (PRs) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib (ECBF+A) Enrollment in expanded ECBF+A cohort completed and data is

RHEA-AI

positive

02/21/23 8:30 AM

Nasdaq : EFTR

clinical trialcovid-19low float

eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs)

RHEA-AI

neutral

01/30/23 8:00 AM

Nasdaq : EFTR

conferenceslow float

eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, announced that the Company will present and host 1x1

RHEA-AI

neutral

01/05/23 4:01 PM

Nasdaq : EFTR

clinical triallow float

eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update

Zotatifin continues to show favorable activity profile, including two confirmed partial responses (PR) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib (ECBF+A), with good tolerability eFFECTOR to focus on front-line PD-L1 ≥ 50% cohort of KICKSTART trial

RHEA-AI

neutral

11/07/22 4:00 PM

Nasdaq : EFTR

earningslow float

eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

- Key executive appointments: Douglas Warner, M.D., as CMO & Mayank Gandhi, M.D., as CBO – - Cohort treating ER+ breast cancer with combination of zotatifin, fulvestrant and abemaciclib has been expanded from 7 patients to 18 patients - - Initiated dosing and completed enrollment in second cohort

RHEA-AI

neutral

10/31/22 2:05 PM

Nasdaq : EFTR

conferenceslow float

eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the management team will participate in and host

RHEA-AI

neutral

10/26/22 8:00 AM

Nasdaq : EFTR

clinical trialcovid-19low float

eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation

RHEA-AI

neutral

09/26/22 8:00 AM

Nasdaq : EFTR

managementlow float

eFFECTOR Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced it has appointed Mayank J. Gandhi, M.D., as chief

RHEA-AI

very positive

09/21/22 9:00 AM

Nasdaq : EFTR

conferenceslow float

eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of

RHEA-AI

neutral

09/14/22 8:00 AM

Nasdaq : EFTR

clinical trialcovid-19low float

eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19

RHEA-AI

neutral

EFTR Data

IndustryPharmaceutical Preparation Manufacturing
Websiteeffector.com
CeoSteve Worland
Security nameeFFECTOR Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees13
Address11180 Roselle St
StateCalifornia
CitySan Diego
Zip92121-1211
CountryUS
Phone18589258215

About eFFECTOR Therapeutics Inc

eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of multiple functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. In addition to the company’s oncology focus, zotatifin is being evaluated as a potential host-directed anti-viral therapy in patients with mild to moderate COVID-19 in collaboration with the University of California, San Francisco, under a $5 million grant sponsored by the Defense Advanced Research Projects Agency.